Spots Global Cancer Trial Database for Intralesional HPV Vaccine for Condylomata

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intralesional HPV Vaccine for Condylomata

Official Title: Therapeutic Intralesional Nonavalent HPV Vaccine for Genital Condylomata in Adults: an Open Label Pilot Study

Study ID: NCT05087849

Conditions

Human Papilloma Virus

Warts

Warts, Genital

Condyloma

Condylomata Acuminata

Interventions

nonavalent human papillomavirus vaccine

Study Description

Brief Summary: This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.

Detailed Description: This is a prospective, open-label, proof-of-concept research study to assess the effectiveness of intralesional nonavalent in the treatment of patients with genital condylomata. The study will be conducted at Zuckerberg San Francisco General Hospital. The planned intervention is to provide 10 subjects with at least 3 genital condylomata with intralesional nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for change in wart size and wart number.